Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/9635

Title: Surrogate end points: hopes and perils
Authors: Alonso Abad, Ariel
Molenberghs, Geert
Issue Date: 2008
Citation: Expert Review of Pharmacoeconomics & Outcomes Research, 8(3). p. 255-259
Abstract: In recent years, the cost of drug development has increased the demands on efficiency in the selection of suitable drug candidates; surrogate end points have emerged to improve this process, hoping that they can help reduce duration and cost of clinical trials. Additionally, they can help in solving ethical issues when measuring the clinical end point involves the application of risky or uncomfortable medical procedures. However, the very mention of surrogate end points has always been controversial, owing in part to unfortunate historical events. As a consequence, there is growing consensus on the use of validated surrogates only. Here, we discuss some of the validation strategies that have recently been proposed and consider the future of surrogate end points in clinical research.
URI: http://hdl.handle.net/1942/9635
DOI: 10.1586/14737167.8.3.255
ISSN: 1473-7167
Category: A3
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version188.76 kBAdobe PDF
Peer-reviewed author version241.45 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.